Webinar Recording: 2011: The Stem Cell Odyssey Continues
In this recording of our 6th annual Stem Cell summit, we review the past, discuss current state, and look forward to the future developments in stem cell research, commercialization, and intellectual property.
Originally recorded May 20, 2011
In this recording of our 6th annual summit, we review the past, discuss current state, and look forward to the future developments in stem cell research, commercialization, and intellectual property. Originally recorded May 20, 2011
- M. William “Willy” Lensch, PhD, Instructor in Pediatrics, Harvard Medical School, Affiliate Faculty and Faculty Advisor for Education, Harvard Stem Cell Institute
- Do We Still Need Embryonic Stem Cells or Has the Research Passed Them By?
- Rekha K. Paleyanda, Ph.D., Senior Business Strategy and Licensing Manager, Massachusetts General Hospital, Partners HealthCare | Research Ventures & Licensing
- The Challenge of Licensing Early Stage Regenerative Medicine and Stem Cell Patents
- Susan R. Windham-Bannister, Ph.D., President and CEO, Massachusetts Life Sciences Center
- Massachusetts’ Efforts to Fund Life Science Companies in Economically Challenging Times
- Ankit Mahadevia, Principal, Atlas Venture, Life Sciences Group
- The Reality of Funding Regenerative Medicine Companies, Including Stem Cell Companies
- Valentin Fulga, M.D., CEO, Hemostemix
- Hemostemix’s Stem Cell Based Therapy and Its Plans for the Future
- John McNeish, Biopharmaceutical Consultant for Regenerative Medicine, Boston Stem Cell, LLC
- A Biopharmaceutical Perspective on Stem Cells and Regenerative Medicine R&D
- Ronald I. Eisenstein, Partner, Nixon Peabody LLP
- The Legal Impact That the ACLU’s Attack on Myriad’s Gene Patents and the Recent Suit Against Monsanto’s Genetic Seed Patents Will Have on Stem Cells
- David S. Resnick, Partner, Nixon Peabody LLP
- The Landscape for Stem Cell Intellectual Property
Click here to view an online recording of this event.
Sponsor in kind
The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.